BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 23422771)

  • 1. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
    Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
    Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
    Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
    Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
    Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
    Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.
    Dhanwal DK; Sharma AK
    Pituitary; 2011 Dec; 14(4):384-7. PubMed ID: 19381817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
    Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
    Shimon I; Benbassat C; Hadani M
    Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report.
    Guastamacchia E; Triggiani V; Tafaro E; De Tommasi A; De Tommasi C; Luzzi S; Sabbà C; Resta F; Terreni MR; Losa M
    Minerva Endocrinol; 2007 Sep; 32(3):231-6. PubMed ID: 17912159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
    Iyer P; Molitch ME
    Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectopic Cavernous Sinus Microprolactinoma Treated Medically.
    Minns RM; Barranco-Trabi J; Yiu AC; Hussain A; Elegino-Steffens DU
    Mil Med; 2023 May; 188(5-6):1304-1306. PubMed ID: 35758408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline.
    Krassas GE; Pontikides N; Kaltsas T
    Horm Res; 1999; 52(1):45-8. PubMed ID: 10640900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
    Barkhoudarian G; Palejwala SK; Ogunbameru R; Wei H; Eisenberg A; Kelly DF
    World Neurosurg; 2018 Oct; 118():118-124. PubMed ID: 30031177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prolactinoma in a child showing high MIB-1 labeling index: a case report].
    Akamine S; Miyamoto T; Sugiura Y; Takehara S; Hiramatsu H; Nishizawa S; Yokota N
    No Shinkei Geka; 2000 Jun; 28(6):547-53. PubMed ID: 10875113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
    Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
    J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
    Cackett P; Eunson G; Bath L; Mulvihill A
    Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giant prolactinomas presenting as skull base tumors.
    Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
    Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prolactinoma treatment status in the cabergoline era].
    Watanabe S; Takano S; Akutsu H; Sato H; Matsumura A
    No Shinkei Geka; 2011 Nov; 39(11):1045-54. PubMed ID: 22036815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.
    Mallea-Gil MS; Cristina C; Perez-Millan MI; Villafañe AM; Ballarino C; Stalldecker G; Becu-Villalobos D
    Endocr Pathol; 2009; 20(1):35-40. PubMed ID: 19172414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary apoplexy due to prolactinoma in a Taiwanese boy: patient report and review of the literature.
    Yang MH; Chuang H; Jung SM; Van YH; Lo FS
    J Pediatr Endocrinol Metab; 2003 Dec; 16(9):1301-5. PubMed ID: 14714755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report of sarcoma of the sella caused by postoperative radiotherapy for a prolactin-producing pituitary adenoma.
    Kurosaki M; Kambe A; Ishibashi M; Watanabe T; Horie Y
    Brain Tumor Pathol; 2014 Jul; 31(3):187-91. PubMed ID: 24446079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.